PL338783A1 - Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors - Google Patents

Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors

Info

Publication number
PL338783A1
PL338783A1 PL98338783A PL33878398A PL338783A1 PL 338783 A1 PL338783 A1 PL 338783A1 PL 98338783 A PL98338783 A PL 98338783A PL 33878398 A PL33878398 A PL 33878398A PL 338783 A1 PL338783 A1 PL 338783A1
Authority
PL
Poland
Prior art keywords
naphtyridin
carboxamides
ligands
oxo
substituted
Prior art date
Application number
PL98338783A
Other languages
English (en)
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of PL338783A1 publication Critical patent/PL338783A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL98338783A 1997-08-25 1998-08-24 Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors PL338783A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
PL338783A1 true PL338783A1 (en) 2000-11-20

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98338783A PL338783A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors

Country Status (24)

Country Link
EP (1) EP1007526A1 (https=)
JP (1) JP2001514181A (https=)
KR (1) KR20010023313A (https=)
CN (1) CN1268136A (https=)
AP (1) AP2000001742A0 (https=)
AU (1) AU753800B2 (https=)
BG (1) BG104192A (https=)
BR (1) BR9811362A (https=)
CA (1) CA2301599C (https=)
EG (1) EG21717A (https=)
HU (1) HUP0003258A3 (https=)
IL (1) IL134291A0 (https=)
IS (1) IS5382A (https=)
LV (1) LV12539B (https=)
NO (1) NO20000822L (https=)
NZ (1) NZ502548A (https=)
OA (1) OA11293A (https=)
PE (1) PE130999A1 (https=)
PL (1) PL338783A1 (https=)
SI (1) SI20270A (https=)
SK (1) SK2162000A3 (https=)
TW (1) TW574221B (https=)
WO (1) WO1999010347A1 (https=)
YU (1) YU10500A (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010308A (pt) * 1999-05-06 2002-01-08 Neurogen Corp Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
AU5289600A (en) 1999-05-25 2000-12-12 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CA2425440C (en) 2000-10-12 2010-04-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
WO2002069948A1 (en) * 2001-03-01 2002-09-12 Pfizer Products Inc. Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2003077857A2 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
JP5373613B2 (ja) * 2006-10-16 2013-12-18 バイオノミクス リミテッド 新規な抗不安薬化合物
ES2610508T3 (es) * 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204813A1 (es) * 1972-05-08 1976-03-05 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampilicina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
HUP0003258A2 (en) 2001-03-28
LV12539B (en) 2001-01-20
WO1999010347A1 (en) 1999-03-04
EP1007526A1 (en) 2000-06-14
HUP0003258A3 (en) 2001-05-28
AU9117398A (en) 1999-03-16
BR9811362A (pt) 2000-08-22
TW574221B (en) 2004-02-01
NZ502548A (en) 2002-06-28
AU753800B2 (en) 2002-10-31
CN1268136A (zh) 2000-09-27
BG104192A (en) 2001-05-31
IS5382A (is) 2000-02-22
OA11293A (en) 2002-11-19
IL134291A0 (en) 2001-04-30
CA2301599A1 (en) 1999-03-04
NO20000822D0 (no) 2000-02-18
SI20270A (sl) 2000-12-31
JP2001514181A (ja) 2001-09-11
PE130999A1 (es) 1999-12-16
CA2301599C (en) 2003-03-25
LV12539A (en) 2000-10-20
SK2162000A3 (en) 2001-03-12
KR20010023313A (ko) 2001-03-26
YU10500A (sh) 2002-10-18
EG21717A (en) 2002-02-27
NO20000822L (no) 2000-04-13
AP2000001742A0 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
PL338783A1 (en) Substituted 4-oxo-naphtyridin-3-carboxamides as ligands of cerebral gaba receptors
PL350095A1 (en) Ligands of melanocortinic receptors
GB9817407D0 (en) Chiral compounds
AU2218997A (en) Certain fused pyrrolecarboxamides as gaba brain receptor ligands
PL341652A1 (en) Derivatives of triazolopyridazine as ligands for gaba receptors
AU2217200A (en) 2-amino-9-alkylpurines: gaba brain receptor ligands
SG71785A1 (en) Deploymerization of polyamides
ZA983736B (en) New compounds
IL135729A0 (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
HUP0004862A3 (en) Novel compounds useful as neuro-protective agents
IL134408A0 (en) Anti-first- pass effect compounds
CZ2000554A3 (cs) Substituované 4-oxonaftyridin-3-karboxamidy jako ligandy mozkových receptorů GABA
AU2653499A (en) Oxo-dipyridoimidazole-carboxamides: gaba brain receptor ligands
ZA976591B (en) Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
GB9706561D0 (en) Alkanoic compounds
ZA9810176B (en) H3 receptor ligands of the phenyl-alkyl-imidazoles type
TW322697U (en) Structure of pre-frying machine
TW383619U (en) Improvement for filter element of filter
PL324063A1 (en) Filtering attachment
HU9701558D0 (en) New compounds
GB9701702D0 (en) Improvements relating to line tensioners
GB9710712D0 (en) Novel compounds
GB9709089D0 (en) Novel compounds
GB9710589D0 (en) Novel compounds
GB9710228D0 (en) Novel compounds